A Pilot Study of a Response Oriented Chemotherapeutic Regimen Combined with Autologous Peripheral Blood Progenitor Cell Transplantation in Aggressive Non-Hodgkin's Lymphoma

References

• McKelvey EM, Gottlieb JA, Wilson HE, Arthur H, Talky RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyl-dauno-mycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mizi EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM, Ding JC, Dart G, Matthews J, Firkin FC. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hanington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A. Comparison of a second-generation combination che-motherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wiknson PM, Kane K, Bentley J, Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Sawada K, Sato N, Kohno M, Handa H, Yasukouchi T, Tan-Ngo M, Hirayama A, Koike T. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: A pilot study for a leukocyte count oriented regimen. Leukemia and Lymphoma 1995; 20: 103–109
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gonn NC, Flesh M. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, Yeap B, Soiffer R, Coral F, Heflin L. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784–791
   PubMed Web of Science ®Google Scholar
• Gulati SC, Shank B, Black P, Yopp J, Koziner B, Straus D, Filippa D, Kempin S, Castro-Malaspina H, Cunningham I. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303–1313
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, Armitage JO. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar
• Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992; 10: 1452–1459
   PubMed Web of Science ®Google Scholar
• Merk K, Idestrom K, Johansson B, Kimby E, Lindemalm C, Osby E, Bjorkholm M. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin's lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. J Haematol 1991; 46: 33–37
   PubMed Web of Science ®Google Scholar
• The non-Hodgkin's lymphoma pathologic classification project. National cancer institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Domizio P, Owen RA, Shepherd NA, Talbot IC, Norton AJ. Primary lymphoma of the small intestine: A clinico-pathological study of 119 cases. Am J Surg Pathol 1993; 17: 429–442
   PubMed Web of Science ®Google Scholar
• Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D. Survival benefit from high-dose therapy with autologous blood progenitor cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586–592
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87–2. J Clin Oncol 1997; 15: 1131–1137
   PubMed Web of Science ®Google Scholar
• Coiffier B, Bryon PA, Berger F, Archimbaud E, Ffrench M, Extra JM, Guyotat D, Fiere D, Gentilhomme O, Magaud JP. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). J Clin Oncol 1986; 4: 147–153
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S, Mailliard J, Okerbloom J, Johnson PS, Howe D. Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 160–164
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, Van Lmhoff GW, Kluin-Nelemans HC, Rae-Maekers JM, Van Oers RH, Haak HL. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051
   PubMed Web of Science ®Google Scholar
• Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Mmelli MF, Calabresi F, Tura S, Mandelli F. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534–542
   PubMed Web of Science ®Google Scholar